Cargando…

196. Assessing the Clinical Impact of Intravenous Acyclovir Dosing in Obese Patients: Should We Be Using Ideal, Adjusted, or Total Body Weight?

BACKGROUND: Obesity impacts the pharmacokinetics and pharmacodynamics of medications. Pharmacokinetic studies of intravenous (IV) acyclovir have demonstrated that dosing obese patients according to their ideal body weight (IBW) may provide a sub-therapeutic dose, while dosing based on total body wei...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulvey, Nicole, Jain, Sumeet, Falsetta, Keith, Doan, Thien-Ly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778324/
http://dx.doi.org/10.1093/ofid/ofaa439.240